Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,625 across all filing types
Latest filing 2022-01-12 Capital/Financing Update
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
ANNOUNCEMENT - COMPLETION OF REGISTRATION OF ISSUANCE OF A SHARES
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of registration of issuance of A shares by RemeGen Co., Ltd. It references prior announcements and regulatory approvals related to the company's share issuance. The text is relatively short (2566 characters) and serves as an update on the progress of a capital raising event rather than a detailed financial report or full filing. It does not contain financial statements or detailed analysis but rather informs about the registration completion of a share issuance. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2022-01-12 English
Monthly Return of Equity Issuer on Movement in Securities for the month ended 31 December 2021
Regulatory Filings Classification · 95% confidence The document is a monthly return report for an equity issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules. It details movements in authorised/registered share capital, issued shares, and confirms compliance with listing rules. It is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, focusing on share capital and share issuance movements for the month ended 31 December 2021. The document is not a financial report, earnings release, or management discussion, but a regulatory filing related to share capital movements and confirmations. It fits best under the category of Regulatory Filings (RNS) as it is a compliance and disclosure document that does not fit other specific categories.
2022-01-06 English
INSIDE INFORMATION ANNOUNCEMENT - NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) GRANTED CONDITIONAL MARKETING APPROVAL FOR DISITAMAB VEDOTIN FOR THE TREATMENT OF HER2 EXPRESSING LOCALLY ADVANCED OR
Regulatory Filings Classification · 95% confidence The document is an announcement by RemeGen Co., Ltd. regarding the conditional marketing approval granted by the National Medical Products Administration (NMPA) for their drug disitamab vedotin for a new indication. It is labeled as an "INSIDE INFORMATION ANNOUNCEMENT" and contains no financial statements or detailed financial data. The content focuses on regulatory approval news rather than financial results or management discussion. The document length is about 5,085 characters, which is relatively short and typical for an announcement. There is no indication that this is a full report like an Annual Report (10-K) or Interim Report (IR), nor is it a transcript, audit report, or other detailed filing. It is a regulatory announcement about a significant event affecting the company. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-01-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2021
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return on movements in securities, specifically focusing on authorized and issued share capital, share movements, and confirmations related to securities issued by the company. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. The document does not contain financial statements, earnings data, or management discussion but rather regulatory compliance information about share capital and securities movements for the month ended 31 December 2021. This type of document is a regulatory filing related to share capital and securities movements, fitting best under the category of Regulatory Filings (RNS) as it does not match other more specific categories like Share Issue/Capital Change (SHA) because it is a monthly return report rather than a specific announcement of a share issue or capital change event.
2022-01-03 English
CLARIFICATION ANNOUNCEMENT
Regulatory Filings Classification · 95% confidence The document is titled as a "Clarification Announcement" issued by RemeGen Co., Ltd. It addresses allegations made in a news article regarding discrepancies and issues related to the company's prospectus for its proposed A share offering. The document provides detailed responses to these allegations, clarifying financial disclosures and legal compliance matters. It references the prospectus and related materials but does not contain actual financial statements or comprehensive financial performance data. The document is an announcement responding to external allegations and clarifying information rather than a full financial report or regulatory filing. It is not a report publication announcement since it contains substantive clarifications and legal responses. Given the nature of the content as a public announcement addressing legal and financial allegations, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-01-03 English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO THE FIRST H SHARE AWARD AND TRUST SCHEME
Transaction in Own Shares Classification · 95% confidence The document is a voluntary announcement by RemeGen Co., Ltd. regarding a share purchase pursuant to the First H Share Award and Trust Scheme. It details the purchase of shares by the Trustee as part of a long-term equity incentive plan for employees. The announcement includes specifics about the number of shares purchased, the price range, and the total consideration. It also mentions that no shares have yet been granted and that further announcements may be made. The document is relatively short (2690 characters) and serves as an update on a share purchase related to an employee incentive scheme, not a full financial report or detailed management discussion. This fits the category of a Transaction in Own Shares (POS), which covers company buybacks or share purchases related to incentive schemes. It is not an announcement of a report publication, nor a regulatory filing or other categories. Therefore, the appropriate classification is POS with high confidence.
2021-12-29 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.